MedTrace Logo

Study of SHP620 (Maribavir) in Healthy Adults

NCT02775240 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-06-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.

Conditions

  • Cytomegalovirus (CMV)

Interventions

DRUG

Digoxin

0.5 mg (2 x 0.25 mg) Digoxin oral dose

DRUG

Maribavir

200mg twice a day for 8 days

DRUG

Dextromethorphan

30 mg oral dose

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-21
Primary Completion
2016-09-12
Completion
2016-09-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775240 on ClinicalTrials.gov